
## Norio Tada

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3019997/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	En face view of the transcatheter heart valve from deep right-anterior-oblique cranial position for coronary access after transcatheter aortic valve implantation: a case series. European Heart Journal - Case Reports, 2022, 6, ytac059.	0.6	3
2	Delivery balloon volume positively correlates with the diameter and effective orifice area of implanted SAPIEN 3. Journal of Cardiology, 2022, , .	1.9	1
3	Clinical outcomes of transcatheter aortic valve implantation (TAVI) in nonagenarians from the optimized catheter valvular intervention <scp>â€</scp> TAVI registry. Catheterization and Cardiovascular Interventions, 2021, 97, E113-E120.	1.7	7
4	Midterm outcomes after the rescue THVâ€inâ€THV procedure: Insights from the multicenter prospective OCEANâ€TAVI registry. Catheterization and Cardiovascular Interventions, 2021, 97, 701-711.	1.7	1
5	Transcatheter aortic valve replacement with Evolut R versus Sapien 3 in Japanese patients with a small aortic annulus: The OCEANâ€TAVI registry. Catheterization and Cardiovascular Interventions, 2021, 97, E875-E886.	1.7	29
6	Impact of diabetes mellitus on outcome after transcatheter aortic valve replacement: Identifying highâ€risk diabetic population from the <scp>OCEANâ€TAVI</scp> registry. Catheterization and Cardiovascular Interventions, 2021, 98, E1058-E1065.	1.7	8
7	Academic Research Consortium High Bleeding Risk Criteria associated with 2-year bleeding events and mortality after transcatheter aortic valve replacement discharge: a Japanese Multicentre Prospective OCEAN-TAVI Registry Study. European Heart Journal Open, 2021, 1, .	2.3	6
8	Influence of polyvascular disease on clinical outcome in patients undergoing transcatheter aortic valve implantation via transfemoral access. PLoS ONE, 2021, 16, e0260385.	2.5	2
9	Prognostic impact and periprocedural complications of chronic steroid therapy in patients following transcatheter aortic valve replacement: Propensityâ€matched analysis from the Japanese OCEAN registry. Catheterization and Cardiovascular Interventions, 2020, 95, 793-802.	1.7	9
10	Update on the clinical impact of mild aortic regurgitation after transcatheter aortic valve implantation: Insights from the Japanese multicenter OCEANâ€TAVI registry. Catheterization and Cardiovascular Interventions, 2020, 95, 35-44.	1.7	12
11	Successful percutaneous treatment of recurrent post-infarction ventricular septal rupture using an Amplatzer duct occluder. Journal of Cardiology Cases, 2020, 21, 12-15.	0.5	3
12	The Predictors of Peri-Procedural and Sub-Acute Cerebrovascular Events Following TAVR from OCEAN-TAVI Registry. Cardiovascular Revascularization Medicine, 2020, 21, 732-738.	0.8	9
13	Transcatheter aortic valve implantation for tricuspid aortic valve with a calcium bridge between the cusps: a case report. European Heart Journal - Case Reports, 2020, 4, 1-5.	0.6	Ο
14	Transcatheter aortic valve implantation after aortic valve neocuspidization using autologous pericardium: a case report. European Heart Journal - Case Reports, 2019, 3, ytz105.	0.6	12
15	Acute Myocardial Infarction Due to Prosthetic Valve Leaflet Thrombosis 15ÂMonths After TAVR. JACC: Cardiovascular Interventions, 2019, 12, e135-e136.	2.9	6
16	Utility of preprocedural multidetector computed tomography in alcohol septal ablation for hypertrophic obstructive cardiomyopathy. Cardiovascular Intervention and Therapeutics, 2019, 34, 364-372.	2.3	4
17	Spontaneous Resolution of Residual Shunting in 2 Compromised Patients after Amplatzer Occlusion of Postinfarction Ventricular Septal Defects. Texas Heart Institute Journal, 2019, 46, 44-47.	0.3	0
18	Incidence, Predictors, and Clinical Impact of Prosthesis–Patient Mismatch Following Transcatheter Aortic Valve Replacement in Asian Patients. JACC: Cardiovascular Interventions, 2018, 11, 771-780.	2.9	80

Norio Tada

#	Article	IF	CITATIONS
19	Anatomical features of the aortic root in aortic stenosis and a novel approach for transcatheter aortic valve implantation. Heart and Vessels, 2018, 33, 908-917.	1.2	5
20	Transcatheter valve-in-valve implantation for failed mitral prosthesis: the first experience in Japan. Cardiovascular Intervention and Therapeutics, 2017, 32, 82-86.	2.3	4
21	Impact of the Clinical Frailty Scale on Outcomes After Transcatheter Aortic Valve Replacement. Circulation, 2017, 135, 2013-2024.	1.6	208

Prognostic Value of Hypoalbuminemia After Transcatheter Aortic Valve Implantation (from the) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 62

23	Gait Speed Can Predict Advanced Clinical Outcomes in Patients Who Undergo Transcatheter Aortic Valve Replacement. Circulation: Cardiovascular Interventions, 2017, 10, .	3.9	57
24	Computed Tomography Score of Aortic ValveÂTissue May Predict Cerebral Embolism During Transcatheter Aortic Valve Implantation. JACC: Cardiovascular Imaging, 2017, 10, 960-962.	5.3	7
25	Transcatheter closure of an atrial septal defect with high risk of erosion using a Figulla Flex II atrial septal defect occluder. Cardiovascular Intervention and Therapeutics, 2017, 32, 436-439.	2.3	0
26	Propensity-matched comparison of percutaneous and surgical cut-down approaches in transfemoral transcatheter aortic valve implantation using a balloon-expandable valve. EuroIntervention, 2017, 12, 1954-1961.	3.2	26
27	Comparison of Results of Transcatheter Aortic Valve Implantation in Patients With Versus Without Active Cancer. American Journal of Cardiology, 2016, 118, 572-577.	1.6	76
28	Pre-Existing Right Bundle Branch BlockÂlncreases Risk for Death After Transcatheter Aortic Valve Replacement With a Balloon-Expandable Valve. JACC: Cardiovascular Interventions, 2016, 9, 2210-2216.	2.9	79
29	Impact of preparatory coronary protection in patients at high anatomical risk of acute coronary obstruction during transcatheter aortic valve implantation. International Journal of Cardiology, 2016, 217, 58-63.	1.7	61
30	Sheathless guide catheter coronary intervention via radial artery: single-center experience with 9658 procedures. Journal of Invasive Cardiology, 2015, 27, 237-41.	0.4	9
31	Percutaneous closure of post-infarction ventricular septal defect using an Amplatzer septal occluder. Cardiovascular Intervention and Therapeutics, 2013, 28, 216-221.	2.3	4
32	The effects of partial use of formula diet on weight reduction and metabolic variables in obese type 2 diabetic patients—Multicenter trial. Obesity Research and Clinical Practice, 2013, 7, e43-e54.	1.8	20
33	Percutaneous focused force aortic valvuloplasty using the buddy-catheter technique. Journal of Invasive Cardiology, 2012, 24, 287-9.	0.4	1
34	A New Assay Method for Remnant Lipoproteins and Its Clinical Significance. The Journal of Japan Atherosclerosis Society, 1992, 20, 79-88.	0.0	5
35	Effect of Niceritrol (Perycit®) on Serum Levels of Lipoprotein (a): Assessing the Effect of Gradually Increased Dosages. The Journal of Japan Atherosclerosis Society, 1992, 20, 625-633.	0.0	0
36	Effect of Large Dose of Niceritrol (Perycit®) on Hypercholesterolemia-by Administering Gradually Increasing Doses. The Journal of Japan Atherosclerosis Society, 1991, 19, 199-208.	0.0	0

Norio Tada

#	Article	IF	CITATIONS
37	Adsorption of Lipoproteins, Lp (a) and RLP (Remnant like particles) by a Dextran Sulfate-Cellulose Column. The Journal of Japan Atherosclerosis Society, 1991, 19, 1135-1141.	0.0	0
38	Effect of Evening Primrose Oil on the Plasma and Red Blood Cells of Hyperlipidemias. The Journal of Japan Atherosclerosis Society, 1988, 15, 1587-1590.	0.0	0
39	Characterization of Lipoprotein Particles Isolated by Monoclonal-anti-apo A-I Affinity hromatography. The Journal of Japan Atherosclerosis Society, 1987, 15, 1089-1096.	0.0	Ο
40	Study on Metabolism of Lipoproteins Using Selected-affinity Columns with Monoclonal Antibodies (II): Analysis of Components in Apo A-I and B-100 Particles. The Journal of Japan Atherosclerosis Society, 1987, 15, 1231-1236.	0.0	0
41	Changes in Plasma and Lipoprotein Lipids, Plasma Apoproteins and Subpopulations of VLDL Particles by Cholesterol Loading in Man. The Journal of Japan Atherosclerosis Society, 1986, 14, 715-722.	0.0	0
42	Effect of Clinofibrate on Plasma Lipoproteins and Apoproteins. The Journal of Japan Atherosclerosis Society, 1984, 12, 341-344.	0.0	0
43	Clinicopharmacological Study on Probucol (The first report). The Journal of Japan Atherosclerosis Society, 1983, 10, 1103-1106.	0.0	2
44	Metabolic Roles of Apolipoprotein C, Sialylation of Apolipoprotein CIII and Its Effects on Lipoprotein Metabolism in Diabetics. The Journal of Japan Atherosclerosis Society, 1983, 11, 1061-1070.	0.0	0
45	Clinicopharmacological Study on Probucol (2). The Journal of Japan Atherosclerosis Society, 1983, 10, 1107-1111.	0.0	0
46	Metabolic Roles of Apolipoprotein C. (I). The Journal of Japan Atherosclerosis Society, 1982, 10, 93-97.	0.0	0
47	Studies on Triglyceride-rich Lipoprotein Metabolism. The Journal of Japan Atherosclerosis Society, 1982, 10, 573-581.	0.0	0